Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

被引：80

作者：

Rule, S. ^{[1
]}

Jurczak, W. ^{[2
]}

Jerkeman, M. ^{[3
]}

Rusconi, C. ^{[4
]}

Trneny, M. ^{[5
]}

Offner, F. ^{[6
]}

Caballero, D. ^{[7
]}

Joao, C. ^{[8
,9
]}

Witzens-Harig, M. ^{[10
]}

Hess, G. ^{[11
]}

Bence-Bruckler, I. ^{[12
]}

Cho, S-G ^{[13
]}

Thieblemont, C. ^{[14
]}

Zhou, W. ^{[15
]}

Henninger, T. ^{[15
]}

Goldberg, J. ^{[15
]}

Vermeulen, J. ^{[16
]}

Dreyling, M. ^{[17
]}

机构：

[1] Plymouth Univ, Sch Med, Plymouth, Devon, England

[2] Jagiellonian Univ, Dept Hematol, Krakow, Poland

[3] Lund Univ, Skanes Univ Hosp, Lund, Sweden

[4] Osped Niguarda Ca Granda, Div Hematol, Dept Hematol & Oncol, Niguarda Canc Ctr, Milan, Italy

[5] Charles Univ Prague, Dept Med 1, Gen Hosp, Prague, Czech Republic

[6] UZ Gent, Dept Oncol, Ghent, Belgium

[7] Hosp Clin Univ Salamanca, Inst Biosanitario Salamanca, Salamanca, Spain

[8] Inst Portugues Oncol Lisboa, Lisbon, Portugal

[9] Champalimaud Ctr Unknown, Hematol, Lisbon, Portugal

[10] Klinikum Ruprechts Karls Univ Heidelberg, Med Klin & Poliklin 5, Heidelberg, Germany

[11] Johannes Gutenberg Univ Mainz, Dept Hematol Oncol & Pneumol, Univ Med Sch, Mainz, Germany

[12] Ottawa Hosp, Gen Campus, Ottawa, ON, Canada

[13] Seoul St Marys Hosp, Seoul, South Korea

[14] Diderot Univ, St Louis Hosp, APHP, Hematooncol, Paris, France

[15] Janssen Res & Dev, Raritan, NJ USA

[16] Janssen Res & Dev, Leiden, Netherlands

[17] LMU, Klinikum Univ Munchen, Dept Med 3, Munich, Germany

来源：

LEUKEMIA | 2018年 / 32卷 / 08期

关键词：

BORTEZOMIB;

D O I：

10.1038/s41375-018-0023-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：1799 / 1803

页数：5

共 10 条

[1]

[Anonymous], BLOOD

[2]

[Anonymous], 2017, IMBRUVICA US PRESCR

[3]

Dreyling M, 2017, ANN ONCOL, V28, P62, DOI [10.1093/annonc/mdx223, 10.1093/annonc/mdx289]

[4] Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study [J].

Dreyling, Martin ;

Jurczak, Wojciech ;

Jerkeman, Mats ;

Silva, Rodrigo Santucci ;

Rusconi, Chiara ;

Trneny, Marek ;

Offner, Fritz ;

Caballero, Dolores ;

Joao, Cristina ;

Witzens-Harig, Mathias ;

Hess, Georg ;

Bence-Bruckler, Isabelle ;

Cho, Seok-Goo ;

Bothos, John ;

Goldberg, Jenna D. ;

Enny, Christopher ;

Traina, Shana ;

Balasubramanian, Sriram ;

Bandyopadhyay, Nibedita ;

Sun, Steven ;

Vermeulen, Jessica ;

Rizo, Aleksandra ;

Rule, Simon .

LANCET, 2016, 387 (10020) :770-778

[5] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma [J].

Fisher, Richard I. ;

Bernstein, Steven H. ;

Kahl, Brad S. ;

Djulbegovic, Benjamin ;

Robertson, Michael J. ;

de Vos, Sven ;

Epner, Elliot ;

Krishnan, Amrita ;

Leonard, John P. ;

Lonial, Sagar ;

Stadtmauer, Edward A. ;

O'Connor, Owen A. ;

Shi, Hongliang ;

Boral, Anthony L. ;

Goy, Andre .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4867-4874

[6] Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study [J].

Goy, Andre ;

Sinha, Rajni ;

Williams, Michael E. ;

Besisik, Sevgi Kalayoglu ;

Drach, Johannes ;

Ramchandren, Radhakrishnan ;

Zhang, Lei ;

Cicero, Sherri ;

Fu, Tommy ;

Witzig, Thomas E. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) :3688-+

[7] Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma [J].

Herrmann, Annina ;

Hoster, Eva ;

Zwingers, Thomas ;

Brittinger, Guenter ;

Engelhard, Marianne ;

Meusers, Peter ;

Reiser, Marcel ;

Forstpointner, Roswitha ;

Metzner, Bernd ;

Peter, Norma ;

Woermann, Bernhard ;

Truemper, Lorenz ;

Pfreundschuh, Michael ;

Einsele, Hermann ;

Hiddemann, Wolfgang ;

Unterhalt, Michael ;

Dreyling, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) :511-518

[8] Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [J].

Hess, Georg ;

Herbrecht, Raoul ;

Romaguera, Jorge ;

Verhoef, Gregor ;

Crump, Michael ;

Gisselbrecht, Christian ;

Laurell, Anna ;

Offner, Fritz ;

Strahs, Andrew ;

Berkenblit, Anna ;

Hanushevsky, Orysia ;

Clancy, Jill ;

Hewes, Becker ;

Moore, Laurence ;

Coiffier, Bertrand .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3822-3829

[9] Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma [J].

Jurczak, Wojciech ;

Ramanathan, Sundra ;

Giri, Pratyush ;

Romano, Alessandra ;

Mocikova, Heidi ;

Clancy, Jill ;

Lechuga, Mariajose ;

Casey, Michelle ;

Boni, Joseph ;

Giza, Agnieszka ;

Hess, Georg .

LEUKEMIA & LYMPHOMA, 2018, 59 (03) :670-678

[10] Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma [J].

Wang, Michael L. ;

Rule, Simon ;

Martin, Peter ;

Goy, Andre ;

Auer, Rebecca ;

Kahl, Brad S. ;

Jurczak, Wojciech ;

Advani, Ranjana H. ;

Romaguera, Jorge E. ;

Williams, Michael E. ;

Barrientos, Jacqueline C. ;

Chmielowska, Ewa ;

Radford, John ;

Stilgenbauer, Stephan ;

Dreyling, Martin ;

Jedrzejczak, Wieslaw Wiktor ;

Johnson, Peter ;

Spurgeon, Stephen E. ;

Li, Lei ;

Zhang, Liang ;

Newberry, Kate ;

Ou, Zhishuo ;

Cheng, Nancy ;

Fang, Bingliang ;

McGreivy, Jesse ;

Clow, Fong ;

Buggy, Joseph J. ;

Chang, Betty Y. ;

Beaupre, Darrin M. ;

Kunkel, Lori A. ;

Blum, Kristie A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (06) :507-516

← 1 →